MOTS-c Peptide Overcomes Liver Cancer Resistance to Apoptosis Under Hypoxia
Background
Hepatocellular Carcinoma (HCC) is a highly aggressive liver cancer with limited treatment options, often developing resistance to therapies. One promising approach involves inducing apoptosis (programmed cell death) using agents like TRAIL (TNF-related apoptosis-inducing ligand). However, the hypoxic (low-oxygen) microenvironment common in solid tumors like HCC often renders cancer cells resistant to TRAIL-induced apoptosis, presenting a significant challenge for effective treatment. This study specifically addresses how to restore TRAIL sensitivity in HCC cells under hypoxic conditions.
Results
The study found that MOTS-c significantly restored sensitivity to TRAIL-induced apoptosis in HCC cells under hypoxic conditions. Specifically, MOTS-c treatment led to a 43% increase in apoptotic cell death when combined with TRAIL compared to TRAIL alone under hypoxia (p<0.01). This effect was dose-dependent, with optimal results observed at 300 nM MOTS-c. Further investigation revealed that MOTS-c achieved this by activating MEF2A, leading to a 2.5-fold upregulation of MEF2A protein levels and a 1.8-fold increase in its transcriptional activity (p<0.001). Knockdown of MEF2A abrogated the protective effect of MOTS-c, confirming its crucial role. MOTS-c treatment under hypoxia resulted in a remarkable 65% reduction in viable HCC cells when combined with TRAIL, effectively overcoming hypoxia-induced resistance.
Why It Matters
This research highlights MOTS-c's potential as a novel therapeutic agent to enhance the efficacy of existing cancer treatments by overcoming drug resistance, particularly in challenging tumor microenvironments like hypoxia. The identification of MEF2A as a key mediator provides a specific molecular target for future drug development. If validated in preclinical models, MOTS-c could be developed into a valuable adjuvant therapy for HCC patients, potentially improving response rates to TRAIL-based treatments. Future steps should include in vivo studies in animal models of HCC to confirm these findings and assess safety.